Neurogene (NGNE) Enterprise Value (2014 - 2026)

Neurogene (NGNE) has 14 years of Enterprise Value data on file, last reported at -$243.2 million in Q1 2026.

• Quarterly Enterprise Value rose 16.89% year-over-year to -$243.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$243.2 million (up 16.89% YoY) and the FY2025 annual result came in at -$269.0 million, up 13.89% from the prior year.
• Enterprise Value rose to -$243.2 million in Q1 2026, from -$269.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$78.5 million in Q3 2023 to a low of -$312.4 million in Q4 2024.
• A 5-year average of -$176.1 million and a median of -$153.9 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 42.43% — and 2023, when it plunged 140.37%.
• Tracing NGNE's Enterprise Value over 5 years: stood at -$82.0 million in 2022, then sank by 140.37% to -$197.2 million in 2023, then sank by 58.45% to -$312.4 million in 2024, then gained by 13.89% to -$269.0 million in 2025, then grew by 9.6% to -$243.2 million in 2026.
• The last three Enterprise Value figures came in at -$243.2 million (Q1 2026), -$269.0 million (Q4 2025), and -$265.4 million (Q3 2025), per Business Quant data.